TRPM4 Expression as a Predictive Biomarker and a Mechanistic Driver of Acetalax Activity in Prostate Cancer: Preclinical Efficacy Studies.
Saved in:
| Title: | TRPM4 Expression as a Predictive Biomarker and a Mechanistic Driver of Acetalax Activity in Prostate Cancer: Preclinical Efficacy Studies. |
|---|---|
| Authors: | Hoshi-Kadonosawa Y; National Cancer Institute Bethesda United States., Reinhold WC; National Cancer Institute Bethesda, MD United States., Taniyama D; National Cancer Institute United States., Inoue Y; United States National Library of Medicine Bethesda United States., Luna A; United States National Library of Medicine Bethesda, MD United States., Kumar S; National Cancer Institute Bethesda, MD United States., Sun NY; National Cancer Institute Bethesda, MD United States., Kim YS; National Cancer Institute Bethesda United States., Yin JJ; National Cancer Institute Bethesda, MD United States., Roper N; National Cancer Institute Bethesda, Maryland United States., Sowalsky AG; National Cancer Institute Bethesda, MD United States., Figg WD; National Cancer Institute Bethesda, MD United States., Takebe N; OU Health Stephenson Cancer Center Oklahoma City, Oklahoma United States., Pommier Y; National Cancer Institute Bethesda, MD United States. |
| Source: | Molecular cancer therapeutics [Mol Cancer Ther] 2026 Apr 22. Date of Electronic Publication: 2026 Apr 22. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
